Condition: Aplastic Anemia · Sponsor: Zhejiang University
This is a single-arm, open-label, single-center, phase I study. The primary objective is to evaluate the safety of CD7 CAR-T Bridging to allo-HSCT therapy for patients with severe aplastic anemia
This description comes directly from the study's public registry record.
He Z Huang, MD · 13605714822 · hehuangyu@126.com
Yongxian Hu, MD · 86-15957162012 · huyongxian2000@aliyun.com
Always discuss trial participation with your own doctor first.
| The First Affiliated Hospital of Zhejiang University School of Medicine | Hanzhou, Zhejiang, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06633328